Imiquimod · Regulatory label update

FDA supplemental approval: Imiquimod (Labeling)

U.S. Food and Drug Administration · June 24, 2026

Insufficient Information Why this matters to you Expert discussion

The material analysed did not support any firm read.

AI Summary

This is a U.S. FDA supplemental approval of a labeling change for imiquimod 5% cream (ANDA091308, Apotex Inc.), approved 24 June 2026. The record is a regulatory action notice only and does not contain clinical trial data, efficacy results, or comparative evidence. It documents a labeling modification to the existing approved topical formulation.

What was studied

Regulatory label update. United States (FDA).

Key findings

Safety

This regulatory record does not contain clinical trial results, efficacy data, or safety outcomes. No comparative efficacy or safety data provided.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

FDA supplemental approval for imiquimod labeling update; regulatory action record containing no clinical trial data or efficacy comparisons.

Study design

As stated by the source record.

SettingUnited States (FDA)

Reported figures

Quoted from the source exactly as published.

Approval date2026-06-24

Active ingredient and strengthImiquimod 5%

FormulationCream, topical

Caveats

This regulatory record does not contain clinical trial results, efficacy data, or safety outcomes.
The specific labeling changes are not detailed in this submission record.
No comparative efficacy or safety data provided.
Approval type is labeling change only; no new indication or formulation change is stated.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory record; no study design applicable.

Directness

insufficient

No clinical outcomes reported in this labeling action.

Consistency

insufficient

Single regulatory submission; consistency cannot be assessed.

Risk of bias

insufficient

Regulatory action; no trial methodology to assess for bias.

Sample adequacy

insufficient

No clinical sample reported in labeling submission.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Drugs@FDA record for application ANDA091308. This is a regulatory action record, not a clinical study. Brand name: IMIQUIMOD. Active ingredient: IMIQUIMOD. Sponsor: APOTEX INC. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-06-24. Products: IMIQUIMOD, CREAM, TOPICAL, IMIQUIMOD 5%.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

ImiquimodApotex